Quan Capital — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Crescendo Biologics develops novel immune cell-enhancing therapeutics for immuno-oncology using its patent-protected Humabody VH platform, a fully human domain technology clinically validated in oncology and immunology.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersSofinnova PartnersAstellas Venture Management LLCEMBL VenturesFuture Planet CapitalAvlar BioVentures+1 more
Adcentrx Therapeutics is a biotech company focused on the discovery and clinical development of antibody-drug conjugates (ADCs) for oncology.
BiotechHealthtech
Hui Li(Founder, President & CEO)in
Co-investorsEight Roads VenturesF-Prime CapitalDelta Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.